FTRE Share Price Performance
US$8.87
1.32 (17.48%)
38.6% undervalued intrinsic discount
US$14.44
Fair Value
Price US$8.87
AnalystConsensusTarget US$14.44
AnalystLowTarget US$5.00
AnalystHighTarget US$22.46
Fair ValueUS$14.44
Share Pricen/a
Fortrea Holdings Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
FTRE Community Narratives
AN
Fair Value US$14.44 38.6% undervalued intrinsic discount
FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value US$5 77.4% overvalued intrinsic discount
Regulation And Pricing Will Erode Margins But May Improve Efficiency
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$22.46 60.5% undervalued intrinsic discount
Global Aging And Digital Trends Will Reshape Clinical Research
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Global Aging And Digital Trends Will Reshape Clinical Research
Key Takeaways Structural cost realignment and advanced digital tools position Fortrea for superior margin expansion and operational efficiency compared to peers. Clinical expertise and leadership changes enhance Fortrea's ability to capture new high-margin revenue streams and support stable, long-term growth.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$22.46
60.5% undervalued intrinsic discount
Fair Value
Profit Margin
1.27%
Future PE
85.44x
Price in 2029
US$30.36
FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
Key Takeaways Robust global demand, favorable demographic trends, and increased R&D create long-term growth opportunities, while AI investments enable operational efficiency and improved margins. Cost optimization, leadership stability, and renewed focus in key market segments drive business momentum and support sustainable earnings growth.Read more
110
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$14.44
38.6% undervalued intrinsic discount
Fair Value
Profit Margin
15.51%
Future PE
4.61x
Price in 2029
US$19.52
Regulation And Pricing Will Erode Margins But May Improve Efficiency
Key Takeaways Growing regulatory barriers, pricing reforms, and client consolidation threaten Fortrea's margins, revenue growth, and demand for core services. Limited digital innovation and high customer concentration increase vulnerability to client loss, hinder competitiveness, and restrict long-term profitability.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5
77.4% overvalued intrinsic discount
Fair Value
Profit Margin
14.2%
Future PE
1.7x
Price in 2028
US$6.62
Trending Discussion
Recently Updated Narratives
AN
FTRE: Margin Recovery And Deleveraging Under New Leadership May Drive Re Rating
Fair Value: US$22.46 60.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside
Fair Value: US$14.44 38.6% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulation And Pricing Will Erode Margins But May Improve Efficiency
Fair Value: US$5 77.4% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Fortrea Holdings Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -10.55
- 18.50%
- -36.21%
- 187.0%
About FTRE
- Founded
- 2023
- Employees
- 14086
- CEO
- WebsiteView website
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
